Amyloid β
Amyloid β denotes peptides of 36–43 amino acids result from the APP (amyloid precursor protein) and are involved in Alzheimer's disease as the main component of the amyloid plaques.
Products for Amyloid β
- Cat.No. Product Name Information
-
GC63273
β-Amyloid (1-14),mouse,rat
-
GC63274
β-Amyloid (1-42), (rat/mouse) (TFA)
-
GC37984
β-Amyloid (1-42), rat
-
GC61394
β-Amyloid (1-42), rat TFA
-
GC37991
β-Amyloid 15-21
-
GC34242
β-Amyloid (1-42), rat TFA
-
GC31146
β-Amyloid (10-35), amide
-
GC31129
β-Amyloid 1-16 (Amyloid β-Protein (1-16))
-
GC31171
β-Amyloid 1-28 (Amyloid β-Protein (1-28))
-
GC30325
β-Amyloid 22-35 (Amyloid β-Protein (22-35))
-
GC31137
β-Amyloid 29-40 (Amyloid beta-protein(29-40))
-
GC31179
β-Amyloid 31-35
-
GC16032
(R,S)-Anatabine
Aβ inhibitor
-
GC16139
(R,S)-Anatabine (tartrate)
Aβ inhibitor
-
GC30952
4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine
-
GC31208
4-(6-Bromo-2-benzothiazolyl)benzenamine
-
GC63502
Aβ/tau aggregation-IN-1
-
GC31259
Aftin-4
-
GC62834
ALZ-801
-
GC35334
Amyloid β Peptide (42-1)(human)
-
GA20735
Amyloid β-Protein (1-42)
For a detailed description of Aβ 1-42, please see product H-1368.
For the preparation of Aβ for experimental use, Fezoui et al. (2000) found that solvation of synthetic peptide with sodium hydroxide (Aβ.NaOH) followed by lyophilization, produced stocks with superior solubility and fibrillogenesis characteristics. Solubilization of the pretreated material with neutral buffers resulted in a pH transition from ≈10.5 to neutral, avoiding the isoelectric point of Aβ (pI≈5.5), at which Aβ precipitation and aggregation propensity are maximal.
-
GA20734
Amyloid β-Protein (1-42)
-
GA20733
Amyloid β-Protein (1-42)
Compared to the inner salt, the HCl salt of Aβ42 aggregates more readily at pH 7.4.
-
GA20732
Amyloid β-Protein (1-42)
Aβ 1-42, 42-residue fragment of amyloid precursor protein, has been found to be a major constituent of the senile plaques formed in the brains of patients with Alzheimer's disease and late Down's syndrome. Aβ 1-42 readily forms neurotoxic oligomers at physiological pH. On the other hand, the peptide shows antimicrobial activity. The sequence of H-1368 corresponds to the human, bovine, canine, feline, ovine, guinea pig, and rabbit Aβ42 peptide.
The peptide has been used to detect amyloid β-protein multimers in the cerebrospinal fluid of Alzheimer's disease patients through fluorescence correlation spectroscopy.
For detailed descriptions of the preparation of Aβ 1-42 monomers and protofibrils please see the papers of Jan, Hartley, and Lashuel, Stine et al. (2011), and of Broersen and colleagues. The findings of Ryan et al. indicate that 10% ammonia disaggregates Aβ42 more efficiently than HFIP.
-
GA20730
Amyloid β-Protein (1-42) (HFIP-treated)
H-7442 was obtained by dissolving Amyloid β-Protein (1-42) (H-1368) in HFIP, aliquoting, and removing the solvent as described in the literature.
-
GA20736
Amyloid β-Protein (1-43)
The amyloid β-protein is a 39- to 43-amino acid polypeptide that is the primary constituent of senile plaques and cerebrovascular deposits in Alzheimer's disease and Down's syndrome. Additionally it acts as an inhibitor of the ubiquitin-dependent protein degradation in vitro.
-
GP10099
amyloid A protein fragment [Homo sapiens]
Apolipoproteins related to HDL in plasma
-
GP10118
Amyloid Beta-Peptide (1-40) (human)
Amyloid precursor protein
-
GP10049
Amyloid Beta-Peptide (12-28) (human)
sequence H2N-VHHQKLVFFAEDVGSNK-OH
-
GP10082
Amyloid Beta-peptide (25-35) (human)
Functional domain of Aβ
-
GC33160
amyloid P-IN-1
-
GP10046
Amyloid Precursor C-Terminal Peptide
For beta amyloid generation
-
GC16243
Amyloid β-Peptide (1-42) (human)
-
GP10057
Amyloid β-Peptide (10-20) (human)
Initiates neurodegeneration in Alzheimer disease
-
GP10094
Amyloid β-peptide (10-35), amide
Truncated peptide model
-
GP10097
Amyloid β-Protein (1-15)
Principal component of amyloid
-
GC39254
Anatabine dicitrate
-
GC11309
ARN2966
APP expression modulator
-
GC19053
Azeliragon
TTP488 is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).
-
GP10083
Beta-Amyloid (1-11)
Amyloidogenic peptide
-
GC34232
Beta-Amyloid(1-14),mouse,rat
-
GC31124
BF 227
-
GC33750
BF-168
-
GC15950
CGP 52411
EGFR inhibitor
-
GC61887
Cl-NQTrp
-
GC14854
Colivelin
Neuroprotective peptide and activator of STAT3
-
GC35720
Colivelin TFA
-
GC14828
CPHPC
used with anti-SAP antibodies to eliminate amyloid deposits
-
GC10230
CRANAD 2
near-infrared probe that binds to Aβ40 aggregates
-
GC12942
DAPT (GSI-IX)
γ-secretase inhibitor,potent and specific
-
GC50733
Davunetide
-
GC13554
Deferoxamine mesylate
An iron-chelating agent
-
GC13256
Dihydroergocristine mesylate
5-HT receptor antagonist and partial agonist of adrenergic and dopaminergic receptors
-
GC31083
DWK-1339 (MDR-1339)
-
GC30823
Edonerpic maleate (T-817 maleate)
-
GC10660
EHT 1864
Rac family small GTPases inhibitor
-
GC10089
EUK 134
Salen-manganese complexes;SOD mimetic
-
GC62966
Ezeprogind disulfate
-
GC61476
Fmoc-Ala-Glu-Asn-Lys-NH2
-
GC15105
FPS-ZM1
A RAGE Inhibitor
-
GC36076
Frentizole
-
GC36110
gamma-Secretase Modulators
-
GN10428
Geniposide
Iridoid glycoside with various bioactivities
-
GN10307
Ginsenoside Re
Ginsenoside Re may have properties that inhibit or prevent the growth of tumors.
-
GN10544
Ginsenoside Rg1
Triterpene saponins/steroid glycosides found in Panax
-
GN10614
Ginsenoside Rg2
Ginsenoside Rg2 may have properties that inhibit or prevent the growth of tumors.
-
GN10799
Ginsenoside Rg3
Ginsenoside Rg3 affects endothelium dependent relaxation in the aorta.
-
GC30892
Glutaminyl Cyclase Inhibitor 1
-
GC31110
Glutaminyl Cyclase Inhibitor 2
-
GC17657
Hoechst 34580
Blue fluorescent dyes
-
GC36247
Hoechst 34580 tetrahydrochloride
-
GC10988
J 147
reduces soluble Aβ40 and Aβ42 levels
-
GC30920
K 01-162 (K162)
-
GC17974
Latrepirdine
Brain cell death inhibitor
-
GC38628
Licochalcone B
-
GC12366
LPYFD-NH2
neuroprotective peptide that binds to amyloid beta (Aβ)
-
GC30884
LX2343
-
GC10894
Methoxy-X04
Fluorescent amyloid β (Aβ) probe
-
GC31285
MK-3328
-
GN10695
Notoginsenoside R1
Notoginsenoside R1 has been shown to exhibit antooxidant,anti-inflammatory,antiapoptotic,and immune-stimulatory properties.
-
GC17037
NQTrp
inhibitor of Alzheimer’s disease-associated amyloid β (Aβ) oligomerization and fibrillization
-
GC13783
Phenserine
acetylcholinesterase inhibitor
-
GC62702
RAGE antagonist peptide TFA
-
GC10425
Ro 90-7501
Inhibitor of amyloid β42 (Aβ42) fibril assembly
-
GC44856
Rutin (hydrate)
Rutin is a natural flavonol glycoside with iron chelating and antioxidant properties.
-
GN10502
Saikosaponin C
Reported to induce cell growth and migration
-
GN10313
Schisantherin B
Extracted from Schisandra chinensis (Turcz.)Baill. seeds and stems;Store the product in sealed, cool and dry condition
-
GC37610
Scyllo-Inositol
-
GC12096
Semagacestat (LY450139)
γ-secretase inhibitor
-
GC37639
Silybin B
-
GC17007
TAE-1
inhibitor of amyloid-β fibril formation and aggregation
-
GC63230
TML-6
-
GC17921
Tolcapone
COMT inhibitor
-
GC17910
Tramiprosate
maintains Aβ in a non-fibrillar form.